Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering recall

Executive Summary

Certain lots of Schering-Plough's Proventil albuterol inhalers, Warrick generic albuterol inhalers and Vanceril (beclomethasone) 42 mcg and 84 mcg inhalers manufactured before Sept. 30, 1999 are being voluntarily recalled because some products may not contain the active drug, the company announced March 29. The recall stems from manufacturing problems noted in October. Vanceril was also recalled in December for the same reason (1"The Pink Sheet" Dec. 6, 1999, In Brief). The most recent inspection of the aerosol line at the Kenilworth, N.J. facility was completed in February, the company said

You may also be interested in...



CFC Albuterol To Be Pulled In 2008; FDA Says HFA Makers Need Ramp-Up Time

FDA is basing its Dec. 31, 2008 deadline for the withdrawal of CFC-containing albuterol on the concern that manufacturers will need additional time to ramp-up production of hydrofluoroalkane products

CFC Albuterol To Be Pulled In 2008; FDA Says HFA Makers Need Ramp-Up Time

FDA is basing its Dec. 31, 2008 deadline for the withdrawal of CFC-containing albuterol on the concern that manufacturers will need additional time to ramp-up production of hydrofluoroalkane products

Schering-Plough Vanceril

Recall issued for 82,000 units of beclomethasone 84 mcg double strength inhalation aerosol convenience pack for the treatment of asthma after Schering discovered that the inhalers may not contain active drug

Related Content

UsernamePublicRestriction

Register

PS035829

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel